Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Europe recasts COVID-19 vaccine playbook after first-round flop

Thu, 01st Apr 2021 18:37

* For a graphic on vaccine roll-out, see: https://tmsnrt.rs/3fzstuP

By John Miller and Ludwig Burger

ZURICH, April 1 (Reuters) - Europe, under fire for fumbling
its vaccine roll-out and fighting a fresh wave of infections, is
scrambling to speed up the pace of injections and avoid being
left further behind by Britain and the United States.

In Paris, the city's hallowed national soccer stadium is
being transformed into a mass vaccination hub, while Italy -
with 20,000 infections daily - has put the army and civil
defence agency in charge, after new Prime Minister Mario Draghi
fired the country's vaccine czar.

Over Easter, Germany's North Rhine-Westphalia state is
relaxing rules on who can get 450,000 doses of AstraZeneca's
vaccine. Clotting concerns have prompted the country to
limit the vaccine to people over the age of 60, but North
Rhine-Westphalia hopes its measures will now allow more people
in that age group to get a first dose.

Originally, it had wanted to give the AstraZeneca vaccine to
pregnant women and their partners, among other priority groups.

"We can't do that anymore, because I assume that those
people ... are under 60," North Rhine Westphalia's Health
Minister Karl-Josef Laumann told reporters.

"We didn't want to bunker these shots, we decided we would
get them via vaccination centres to people as quickly as
possible."

Europe's urgency to reverse what the World Health
Organization branded on Thursday an "unacceptably slow" start to
vaccinations is growing, as variants first detected in Britain,
South Africa and now Brazil whip up angst that acting too slowly
will let the virus proliferate again.

The chaos of Europe's roll-out has been exacerbated by
squabbling over vaccine exports, health concerns over
AstraZeneca's vaccine and some temporary delivery delays
affecting Pfizer, Moderna and AstraZeneca
vaccines.

The European Union was slower than Britain and the United
States, not only to order vaccines last year from companies but
also in approving them. Even once they were approved,
vaccination rates have been disappointing.

The WHO estimates just 4% of 750 million people in 53
countries across continental Europe, from wealthier Scandinavia
to poorer Balkan countries, have been fully vaccinated, a
quarter of the U.S. count.

While the European Union's vaccination rate is slowly
climbing, only 13.4% of adults in the bloc have had at least one
shot, according to Europe's vaccine tracker.

By contrast, more than half of adult Britons and 38% of U.S.
adults have received at least one dose, official figures and
Reuters calculations show.

Still, the situation is improving: A Reuters analysis shows
the seven-day average for the four largest countries - Germany,
France, Italy and Spain - was at its highest yet during the last
week.

Since Spain resumed AstraZeneca shots on March 24 after
suspending them temporarily over clotting concerns, its
seven-day rolling average of vaccinations rose to nearly 200,000
shots a day, from 95,283 daily a week earlier, Spanish officials
said.

The country is now converting venues like conference centres
and, like France, football stadiums, into mass vaccination
centres, and expects to inoculate 70% of its 47 million
population by the end of summer.

Spanish Health Minister Carolina Darias has said that April
will be "an inflection point", as more vaccines flood into the
country.

The EU expects a major ramp-up of deliveries in the second
quarter will be sufficient to inoculate at least 255 million
people, or 70% of its adult population, by July.

About 200 million doses of Pfizer-BioNTech's vaccine are due
in the quarter, enough for 100 million people, while deliveries
of Johnson & Johnson's single-dose shot will start this
month.

VETS, DENTISTS, COMPANIES

France is also converting veterinarian and dentists' offices
into vaccine centres, while Italy has abandoned primrose-shaped
pavilions in its squares and is getting doctors, dentists and
pharmacists to dispense doses instead. The aim is to more than
double daily vaccinations to half a million from 230,000
currently.

Pharmacies in Switzerland are also preparing to start
offering doses to people over 65 this month, but the government
expects that once mass vaccinations become possible, likely
sometime in May, private companies will have a role, similar to
flu clinics some offer each year to employees.

The Swiss government expects 10.5 million doses by July,
enough for roughly 5.2 million people.

"There won't just be shots in vaccination centres, doctors
and pharmacists," Swiss Health Minister Alain Berset said on
Wednesday. "That's something we're hoping for, something we're
supporting."

(Reporting by John Miller in Zurich, Ludwig Burger in
Frankfurt, Emilio Parodi in Milan, Francesco Guarascio in
Brussels, Matthias Blamont in Paris, Maria Sheahan in Berlin,
Nathan Allen in Madrid;
Editing by Josephine Mason and Susan Fenton)

More News
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.